40 million deaths by 2050: toll of drug-resistant infections to rise by 70%
top of page
NovoBind
Preventing Devastating Diseases
NovoBind
Preventing Devastating Diseases
Rising to the challenge with best in class evidence based solutions
Working to combat rising resistance to anti-infectives and their accumulating residue in the environment, NovoBind develops next-generation biologics that target and neutralize the specific bacteria, viruses, and parasites that cause intestinal ailments in livestock, aquaculture, and pets.
Our novel biotherapeutic solutions (NBXs) are based on single-domain antibodies and complementary to conventional treatments.
bottom of page